All News
Are Rheums Attending ACR 2020?
ACR 2020 (aka ACR Convergence) is just around the corner, with the opening ceremonies and lecture starting Thursday, November 5th; followed by the full meeting beginning the next morning, Friday November 6th.
Read Article
RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)
Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
Read Article
Abatacept in Early Systemic Sclerosis (ASSET study)
An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).
Read Article
FDA Invites Patient Input on Systemic Sclerosis Drug Development
While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.
Read Article
Guselkumab, an IL-23 Inhibitor, Effective in Psoriatic Arthritis
The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.
Read Article
Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction
JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.
Read Article
Vedolizumab Promising in Immune-Related GI Events
Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.
Read Article
Immune Necrotizing Myopathy
A full read review of immune-mediated necrotizing myopathy is portrayed as a distinct subtype of inflammatory myopathies first described in 2004.
Read Article
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Philip Robinson philipcrobinson ( View Tweet)
Peter Nash drpnash ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)